anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Atrial fibrillation (AF) is the most common arrhythmia in the general population, causing substantial economic burden, morbidity and mortality. The incidence rate and risk of AF in patients with SSc are unclear. We aimed to assess the incidence rate of AF in patients with SSc and the risk of incident AF in patients with SSc compared with the general population.
METHODS: The Korean National Health Insurance Service database was used as the data source. Patients with claims data for SSc between 2010 and 2017 were extracted from the database along with 1:5 age- and sex-matched controls. The index date was the earliest date with claims data for SSc between 2010 and 2017. The follow-up duration was from the index date to 2019. Multivariable Cox proportional hazard models were used to estimate the hazard ratio (HR) and 95% CI for AF in patients with SSc.
RESULTS: Overall, 2519 patients with SSc and 12 595 age- and sex-matched controls were included. Over a mean follow-up duration of 5.2 years (s.d. 2.6), the incidence rates of AF were 3.52 and 1.68 per 1000 person-years for patients with SSc and controls, respectively. Compared with controls, patients with SSc had a significantly higher risk of incident AF [adjusted HR 2.095 (95% CI 1.466, 2.994)].
CONCLUSION: Patients with SSc had a 2-fold higher risk of incident AF than controls. Given the significant economic burden, morbidity and mortality that AF poses, close monitoring for incident AF in patients with SSc is warranted.
1,129,811. Coated aspirin preparations. ASPRO-NICHOLAS Ltd. 20 Dec., 1965 [21 Sept., 1964], No. 38361/64. Heading A5B. Aspirin particles or crystals are coated with polysalicylides {including salicylsalicylate) -o give a product which may be used in pharmaceutical formulations, e.g. tablets and capsules. The coating may be effected by conventional pan-coating techniques using solutions of he polysalicylides in volatile solvents or by coprecipitation of salicylic acid and polysalicylides under controlled conditions. Other medicaments may be incorporated and additional coatings may be present between the aspirin and polysalcylide or overlaying the coated particle.
To investigate the clinical efficacy of acupuncture combined with biofeedback electrical stimulation on female stress urinary incontinence. Ninety patients diagnosed in a hospital between January 2020 and January 2021 were randomly divided into three groups (A, B and C). Group A was treated with biofeedback electrical stimulation, 3 times a week for 30 min for 15 times. Group B used acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday-Friday, 30 min each, for a total of 10 times. Group C was treated with acupuncture combined with biofeedback electrical stimulation. All three groups were combined with pelvic floor muscle training. Following treatment, the changes in class I and II muscle fibre strength, ICI-Q-SF score and urine leakage in the 1-hour pad test were compared. Prior to treatment, there was no significant difference in the general data of the three patient groups, as well as class I and II muscle fibre strength, ICI-Q-SF score and 1-hour urinary pad test (P > 0.05). Following treatment, class I and II muscle fibre strength in groups A and C improved compared with before, with statistical significance (P < 0.05); there was no significant difference in group B (P > 0.05). In the three groups, ICI-Q-SF scores and 1-hour urinary pad test results were lower compared with before (P < 0.05), with those in group C better than those in groups A and B (P < 0.05). The treatment efficiency of the three patient groups was 86.7%, 83.3% and 96.7%, respectively. Combined acupuncture and biofeedback electrical stimulation can improve pelvic floor muscle strength, urine leakage and quality of life, and can be superior to biofeedback and acupuncture treatment alone.
Glucose monitoring is essential for patients receiving insulin therapy. Hypoglycemia is the most common adverse reaction associated with insulins, including AFREZZA. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). 

The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulation. AFREZZA has a distinct time action profile [see Clinical Pharmacology (12)], which impacts the timing of hypoglycemia. Hypoglycemia can happen suddenly, and symptoms may differ across patients and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using certain medications [see Drug Interactions (7.4)], or in patients who experience recurrent hypoglycemia. 

Factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication [see Drug Interactions (7)]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.6, 8.7)]. 

Risk Mitigation Strategies for Hypoglycemia

Patients and caregivers should be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
Procedure : Beside 1cm of ST 36 and PC 6 are selected( not meridian point), subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
Cohort 2 includes approximately 1000 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 2 participants and they can initiate which ever contraceptive method they want at no cost to them for three years.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, and can be used for integrated treatment of purulent cholangitis by external percutaneous transhepatic drainage and laser and antibiotic therapy. That is ensured by ultrasound-aided percutaneous transhepatic drainage. Then Cefoperazone 2 g in 100 ml of 0.9% saline solution in a plastic package is exposed to low-intensity infra-red pulse laser light at wave length 0.89 mcm, power 200 mWt and frequency 1500 Hz for 6 minutes. Thereafter, the exposed antibiotic substance is introduced intravenously drop-by-drop for 30 minutes. Simultaneously, blood is exposed intravenously to continuous laser light at wave length 0.63 mcm, power 2 mWt for 30 minutes. The therapeutic course of laser and antibiotic therapy is 5-10 days. ^ EFFECT: method allows preventing purulent-septic complications represented by hepatic abscesses and hepatic failure. ^ 3 cl, 2 ex
The invention discloses a multifunctional supermolecule hydrogel for preventing postoperative tissue adhesion and a preparation method thereof. The hydrogel is composed of an injectable temperature-sensitive gel forming material, an active oxygen scavenging drug and a polyphenol compound. When in preparation, the three components are uniformly mixed in water according to a certain sequence to obtain the multifunctional supermolecule hydrogel for preventing postoperative tissue adhesion. Wherein, 0.1 to 30 weight percent of injectable temperature-sensitive gel forming material, 0.01 to 10 weight percent of active oxygen scavenging medicament and 0.1 to 50 weight percent of polyphenol compound. The gel material can be locally applied in laminectomy to prevent and treat epidural fibrosis adhesion and tissue adhesion after other surgical operations. Modes of administration include subcutaneous injection, intraluminal injection, painting, and combinations of any of the above. The hydrogel prepared by the invention has proper temperature-sensitive sol-gel phase transition temperature, proper biological adhesion capability and ideal viscoelasticity and flexibility.
BACKGROUND: To investigate factors associated with different reproductive outcomes in patients with Caesarean scar pregnancies (CSPs).
METHODS: Between May 2017 and July 2022, 549 patients underwent ultrasound-guided uterine aspiration and laparoscopic scar repair at the Gynaecology Department of Hubei Maternal and Child Health Hospital. Ultrasound-guided uterine aspiration was performed in patients with type I and II CSPs, and laparoscopic scar repair was performed in patients with type III CSP. The reproductive outcomes of 100 patients with fertility needs were followed up and compared between the groups.
RESULTS: Of 100 patients, 43% had live births (43/100), 19% had abortions (19/100), 38% had secondary infertility (38/100), 15% had recurrent CSPs (RCSPs) (15/100). The reproductive outcomes of patients with CSPs after surgical treatment were not correlated with age, body mass index, time of gestation, yields, abortions, Caesarean sections, length of hospital stay, weeks of menopause during treatment, maximum diameter of the gestational sac, thickness of the remaining muscle layer of the uterine scar, type of CSP, surgical method, uterine artery embolisation during treatment, major bleeding, or presence of uterine adhesions after surgery. Abortion after treatment was the only risk factor affecting RCSPs (odds ratio 11.25, 95% confidence interval, 3.302-38.325; P < 0.01) and it had a certain predictive value for RCSP occurrence (area under the curve, 0.741).
CONCLUSIONS: The recurrence probability of CSPs was low, and women with childbearing intentions after CSPs should be encouraged to become pregnant again. Abortion after CSP is a risk factor for RCSP. No significant difference in reproductive outcomes was observed between the patients who underwent ultrasound-guided uterine aspiration and those who underwent laparoscopic scar repair for CSP.
Pneumonia complicating stroke is very difficult to manage and has a very poor prognosis, leading to a significantly higher risk of death. Oral opportunistic pathogens have been reported to be associated with the incidence of pneumonia among non-stroke immunocompromised subjects. Preliminary studies found that patients with stroke had higher carriage rates of oral opportunistic pathogens than healthy subjects. Therefore, investigators hypothesize that pneumonia complicating stroke is associated with oral opportunistic pathogens, and hyperbaric oxygen therapy may reduce the incidence of pneumonia complicating stroke by increasing the flow of saliva, which can affect the species and relative abundance of oral opportunistic pathogens. In order to prove this, investigators need to (1) firstly conduct a randomized controlled trial to confirm whether hyperbaric oxygen therapy is able to reduce the levels of plaque, and the incidence of pneumonia complicating stroke at clinical level; (2) secondly employ metagenomics analysis to compare oral rinse samples and respiratory samples, and to identify pneumonia-associated "oral opportunistic pathogens group"; (3) finally elucidate how hyperbaric oxygen therapy influences the species and relative abundance of oral opportunistic pathogens. This proposed study will provide evidence for the integration of hyperbaric oxygen therapy as part of interdisciplinary stroke rehabilitation.
An automated high resolution/definition image storage retrieval, and transmission system provides fast, efficient access to medical diagnostic images, e.g. X-ray images, simultaneously to a pluraity of requesting subscribers. This overcomes significant limitations of the prior art system that allowed only one user at a time to view a diagnostic image film that had to be physically transported to a different location for each viewing. The system digitizes images and stores the resultant data in a hierarchically compressed format on CD-ROMs (48). The data are subsequently downloaded, via the telephone lines, to a requesting subscriber in an optimal fashion. The data that are sent initially are used to create an initial, coarse, display of the image. Subsequent data are used to refine the resolution of the displayed image, up to a resolution limit set by the display terminal (20). This progressive enhancement process can be guided by the remote subscriber, who can select the most interesting areas of the image, to receive priority in the enhancement process.
1. A process for the preparation of the compound of formula (I)   comprising: i) reacting a p-nitrophenylsulfonyl group with a compound of formula (A)   in which P is an amine-protecting group; ii) deprotecting the resultant compound of step i); iii) reacting the resultant compound of step (ii) with a tetrahydrofuryloxy carbonyl group; or reacting the resultant compound of step ii) with phosgene, or equivalent, and reacting the resultant intermediate with (S)-tetrahydro-3-furanol; and iv) reducing the resultant compound of step iii) to form a compound of formula (I). 2. A process as claimed in claim 1 in which the protecting group P in the compound of formula (A) is an alkyl, aryl, benzyl or hetero carbamate, alkyl or aryl amide, or silyl group. 3. A process as claimed in claim 2 in which the protecting group P in the compound of formula (A) is t-butyl carbamate. 4. A process as claimed in claim 1 in which the p-nitrophenylsulfonyl group in step i) is a p-nitrophenyisulfonyl halide. 5. A process as claimed in claim 1 in which step i) is carried out in dimethylacetamide or toluene. 6. A process as claimed in any preceding claim in which step ii) is carried out in ethanol or toluene. 7. A process as claimed in claim 1 in which the step ii) product is crystallised as a solvate. 8. A process as claimed in claim 1 in which step iii) is carried out by reacting (S)-tetrahydro-3-furanol with 1,1'-carbonyidiimidazole and the step ii) product in a single step. 9. A process as claimed in claim 8 in which step iii) is carried in ethyl acetate. 10. A process as claimed in claim 1 in which step iv) is carried out by treating the step iii) product with palladium under a hydrogen atmosphere. 11. A process as claimed in claim 10 in which step iv) is carried out in isopropanol. 12. The compound (2R,3S)-N-(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzene sulphonamide hydrochloride and solvates thereof.
Subjects will receive a single dose of GSK525762 10 mg on day 1 followed by 200 mg Itraconazole BID on day 3. On day 4 to day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On day 7 subjects will receive a single dose of GSK525762 5 mg or GSK525762 10 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
Cryptorchidism is the most frequent congenital defect of the male newborn. It requires surgery in childhood, increases the risk of fertility disorders and cancer. As a major public health objective, it's the subject of numerous recommendations. Its frequency is increasing in some countries faster than a single genetic cause could not explain it. It may occurs in a geographic cluster. The cause of cryptorchidism involves genetic, hormonal and environmental factors. Animal studies suggest that endocrine disruptors interfere with fetal testicular migration. The aim of the study is to find out if some environmental exposition may be associated with cryptorchidism.
The invention discloses a novel antibacterial peptide based on MCR-1 protein and application thereof. The sequence of the antibacterial peptide is shown as SEQ ID NO.1 or SEQ ID NO. 2. The synthetic length of the antibacterial peptide is shorter, so that the production cost can be greatly reduced, and meanwhile, the immunogenicity and cytotoxicity of the antibacterial peptide can be effectively reduced. Experiments also prove that the two small molecular peptides can be combined and destroy bacterial cell membranes to play a role, and have broad-spectrum antibacterial activity in vivo and in vitro. The antibacterial short peptide can be used for synergism with colistin, obviously improves antibacterial activity of the colistin, can be used in combination, and provides a new treatment scheme for treatment of drug-resistant bacterial infection of colistin.
1,161,333. Hog cholera vaccine. CHAS. PFIZER & CO. Inc. 31 Oct., 1966 [6 May, 1966], No. 48762/66. Heading A5B. Inactivated hog cholera vaccine is prepared by growing a vaccine virus 'by infecting a swine tissue culture monolayer e.g. swine testicle tissue with virulent hog cholera virus at a pH of 7.2 to 7.6 until substantial virus replication has occurred, freezing said resulting vaccine virus followed by thawing said vaccine virus and recovering the virulent virus, inactivating said virulent virus by (i) combining said virulent virus with aqueous toluidine blue said toluidine being blue added in an amount to provide a final concentration of 2 mcgs. of toluidine blue per ml. of vinus, and irradiating the resulting mixture with light or by (ii) use of hydroxylamine or ethylene oxide, and harvesting the inactivated vaccine (product. The harvesting of the inactivated product Imay be performed by absorbing the virus on hydrated aluminium oxide to precipitate a mixture comprising inactivated virus and hydrated aluminium oxide and subsequently reconstituting the precipitate in phosphate buffered saline.
PURPOSE:A composition capable of improving metabolism of lipoid, suppressing eliminating fatness, comprising a substance like saponin and a purified protein separated from soybean as active ingredients. CONSTITUTION:A composition for suppressing fatness, containing a minimum amount of saponin possible, having no unreasonableness with respect to health, providing suppressing or eliminating effects on fatness, obtained by blending 1pt. wt. substance like saponin separated from soybean, adzuki bean, or carrot with 10-40pts.wt. purified protein separated from soybean. Powder as it is, granule, tablet, capsule, etc. are used as the dosage form. It may be added to processed foods such as cakes, breads, dairy products, soybean milk, etc. and used. This composition having the substance like saponin in an amount extremely reduced by addition of the protein of soybean having improved nutritively balanced amino acids is usable for a wide age range including growth period.
Although psychological factors such as anxiety, depression, and pain catastrophizing are known to influence pain outcomes in chronic pain populations, there are mixed results regarding whether they influence experimental pain outcomes in pain-free individuals. The objectives of this study were to determine the associations between psychological factors and experimental pain outcomes in pain-free adolescents and adults. Relationships between anxiety, depression, and pain catastrophizing and experimental pain outcomes across 8 different studies (total N = 595) were examined in different populations of pain-free adult and adolescent participants. Analyses were conducted with and without controlling for sex, age, and race. Studies were analyzed separately and as part of an aggregate analysis. Individual study analyses resulted in 136 regression models. Of these, only 8 models revealed a significant association between psychological factors and pain outcomes. The significant results were small and likely due to Type 1 error. Controlling for demographic factors had minimal effect on the results. The aggregate analyses revealed weak relationships between anxiety and pressure pain threshold (Fisher's z = -.10 [-.19, -.01]), anxiety and cold pain intensity ratings (Fisher's z = .18 [.04, .32]), and pain catastrophizing and pressure pain threshold (Fisher's z = -.14 [-.26, -.02]). Sample size calculations based on the aggregate analyses indicated that several hundred participants would be required to detect true relationships between these psychological factors and pain measures. The overall negative findings suggest that in pain-free individuals, anxiety, depression, and pain catastrophizing are not meaningfully related to experimental pain outcomes. PERSPECTIVE: Psychological variables have been shown to predict pain outcomes in chronic pain populations but these relationships may not generalize to pain-free populations. An analysis of 595 pain-free individuals across 8 studies in our lab revealed that anxiety, depression, and pain catastrophizing were not meaningfully related to experimental pain outcomes.
Many men develop urine leakage after radical prostatectomy. Usually it is temporary, but pelvic floor muscle training including bladder control strategies has been shown to reduce the severity of incontinence and reduce the time to regaining continence. This study will test an evidence-based pelvic floor muscle training program that has been adapted to telehealth format and pilot tested in a VA-funded pilot/developmental trial. Training is begun 1-4 weeks before surgery and continued 6 months after surgery. Content is accessed on a secure website in daily 10-minute sessions which transition to weekly sessions for post-operative months 3-6. In the investigators' pilot study, Veterans reported that they appreciated receiving the training in the privacy of their homes, enjoyed the interactive style of the learning experience, and felt better prepared to deal with urine leakage and empowered with new knowledge and skills to help themselves.

This study is a randomized, controlled trial of the telehealth-delivered, evidence-based, intervention developed in the pilot/developmental study. Participants will be randomized 1:1 to treatment or to a control group. Content for both control and treatment groups includes general information about prostate cancer; perioperative care; wetness, odor and skin care management. The treatment group will ALSO receive pelvic floor muscle training and bladder control strategies. Outcomes are measured with brief validated questions administered by the telehealth platform, and again at 9 and 12 months by mailed questionnaire or the telehealth platform.
This arm will be enrolled in the online course run by Happy Bellies Nutrition https://www.happybelliesnutrition.com/ibs-gentle-group-program. The Happy Bellies nutrition course has 5.5 hours of total video content and optional biweekly group calls via Zoom (45-minutes per session). This course is designed to take 12 weeks to complete. The participants would have access to the content for one year.
Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment comprising leuprolide acetate or goserelin intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.